[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"drug-use\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:drug-use":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,41,69,92,124,161,183,214,243,279,313,339,364,395,421,458],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100626290","project-reach-a-comprehensive-telehealth-intervention-at-syringe-service-programs-to-engage-people-who-use-drugs-100626290",false,"NCT07433712","Project REACH: A Comprehensive Telehealth Intervention at Syringe Service Programs to Engage People Who Use Drugs","People Who Use Drugs Inclusion Criteria:\n\n* 18 years of age or older\n* able to speak and understand English\n* have used an illicit substance at least once in the past year\n* have lived in the study area (in or near their city of their recruitment) for at least 6 months\n* have active health insurance by the start of the Project REACH trial date\n\nPeople Who Use Drugs Exclusion Criteria:\n\n* Unable or unwilling to provide informed consent\n\nStakeholder Inclusion Criteria:\n\n* 18 years of age or older\n* able to speak and understand English\n* currently employed or volunteering with the PCC or an SSP enrollment site for at least one year at the time of the interview OR hired as a study navigator at one of the four enrollment sites\n\nStakeholder Exclusion Criteria:\n\n* Unable or unwilling to provide informed consent",true,"ALL","18 Years",{"count":19,"type":20},121,"ESTIMATED","INTERVENTIONAL",[23],"NA","This trial will assess the feasibility, acceptability, and preliminary effectiveness of Project REACH (Remote Engagement \\& Access for Community Health), a telehealth intervention at syringe service programs (SSP) to improve access to HIV-related evidence-based interventions (EBI) for people who use drugs including those who inject them.",[26,27],"Substance Use","Drug Use","RECRUITING","2026-05-18",{"date":31,"type":32},"2026-05-19","ACTUAL",{"date":34,"type":32},"2026-05-06",{"date":36,"type":20},"2028-05-01",{"name":38,"class":39},"University of Minnesota","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":40},"100520497","families-with-pride-familias-con-orgullo-100520497","NCT06057337","Families With Pride (\"Familias Con Orgullo\").","Promoting Health and Reducing Risk Among Hispanic Sexual Minority Youth and Their Families","Inclusion Criteria:\n\n* Youth, 13 - 19, who report at least one of the following: a) identify as gay, lesbian, or bisexual, b) reports same sex attraction, or c) reports same-sex sexual behavior.\n* Adolescent has disclosed their sexual minority status to at least one parent.\n* Adolescent is of Hispanic immigrant origin, defined by having at least one parent that self-identifies as Hispanic (English and Spanish speaking Hispanics can participate in the study).\n* Adolescent lives with an adult parent who is willing to participate.\n\nExclusion Criteria:\n\n* Adolescent identifies as transgender.","13 Years","19 Years",{"count":51,"type":20},306,[23],"This study will evaluate the effects of a parenting intervention for Hispanic sexual minority youth in preventing\u002Freducing drug use and depressive symptoms. It will also examine whether the intervention improves parent social support for the adolescent, parent acceptance, family functioning, and whether it reduces general stress and stress associated with being a Hispanic sexual minority.",[55,27],"Depression",[57,58,59],"randomized controlled trial","Hispanic sexual minority youth","parent-centered","2026-05-08",{"date":62,"type":32},"2026-05-13",{"date":64,"type":32},"2024-03-11",{"date":66,"type":20},"2029-12-28",{"name":68,"class":39},"University of Miami",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":40},"100632011","digital-prep-micro-intervention-for-pwud-in-kazakhstan-100632011","NCT07508137","Digital PrEP Micro-Intervention for PWUD in Kazakhstan","Digital Micro-Interventions to Reduce Stigma-Driven Barriers and Improve PrEP Readiness Among People Who Use Drugs in Kazakhstan","Inclusion Criteria:\n\n* Self-reported drug use within the past six months\n* HIV-negative or unknown HIV status (self-reported)\n* Not currently taking PrEP\n* Able to provide informed consent\n* Have access to a personal mobile phone capable of receiving Telegram or WhatsApp messages\n\nExclusion Criteria:\n\n* Are unable to provide informed consent\n* Do not have access to a mobile device for digital message delivery\n* Are currently enrolled in another PrEP behavioral intervention study",{"count":77,"type":20},40,[23],"This study is a mixed-methods pilot designed to evaluate the feasibility, acceptability, and appropriateness of a brief digital micro-intervention aimed at reducing stigma-related barriers to pre-exposure prophylaxis (PrEP) engagement among people who use drugs (PWUD) in Kazakhstan. Participants will complete baseline and post-intervention surveys and receive structured informational content via Telegram or WhatsApp over approximately 2-3 weeks. The intervention focuses on addressing anticipated stigma, confidentiality concerns, and misinformation that may prevent PWUD from seeking PrEP services. No clinical procedures, medication provision, or biological specimen collection are involved.",[27,81],"HIV","NOT_YET_RECRUITING","2026-03-27",{"date":85,"type":32},"2026-04-02",{"date":87,"type":20},"2026-04",{"date":89,"type":20},"2027-10",{"name":91,"class":39},"Yale University",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100498904","harm-reduction-services-100498904","NCT05776316","Harm Reduction Services","Culturally Response Integrated Harm Reduction Services for Black and Latinx People Who Use Drugs","HRS","Inclusion Criteria:\n\n* at least 18 years of age\n* self-identified as misusing opioids +\u002F- other substances (stimulants) in the past 30 days, confirmed by interview using DSM-5 criteria\n* English or Spanish speaking\n* able to provide informed consent.\n\nExclusion Criteria:\n\n* inability to provide informed consent or participate in the study procedures as proposed in the consent\n* active suicidal or homicidal ideation or an unstable psychotic disorder (schizophrenia, schizoaffective disorder) or mood disorder (bipolar disorder, severe major depressive disorder)\n* an unwillingness to be randomized.\n* are prisoners",{"count":101,"type":20},200,[23],"The purpose of this study is to assess whether an integrated harm reduction intervention (IHRI), compared to harm reduction (HR) services as usual, will improve harm reduction service utilization among Black and Latinx people who use drugs (PWUD).",[27,105,106],"Substance Abuse","Mental Illness",[108,109,110,27,111,112,113],"Harm Reduction","Latinx\u002FHispanix","Black\u002FAfrican American","Cocaine","Opioids","Methamphetamines","2026-03-17",{"date":116,"type":32},"2026-03-19",{"date":118,"type":32},"2024-11-25",{"date":120,"type":20},"2028-03-28",{"name":122,"class":39},"NYU Langone Health",3,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":15,"sex":16,"minAge":132,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":137,"conditions":138,"keywords":146,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":40},"100580635","phase-2-family-acceptance-project-online-pilot-rct-100580635","NCT06839859","Family Acceptance Project Online (Pilot RCT)","An Online Family-based Program to Reduce Inequity Among Sexual and Gender Minority Youth of Color (Pilot RCT)","FAP-O","Inclusion Criteria (youth):\n\n1. Identify as a sexual\u002Fgender minority (including youth questioning their sexual orientation and\u002For gender identity AND their identity must be known to their participating caregiver).\n2. Identify as a person of color\u002Fbelonging to a minority racial and\u002For ethnic group.\n3. Be between the ages of 14 and 25 years\n4. Read and speak English\n5. Live in the United States\n6. Report consistent access to a phone, tablet, and\u002For computer with high-speed internet access\n7. Report an ability to attend eight, two-hour online sessions at pre-determined times\n8. Report moderate to high levels of caregiver\u002Ffamily rejection\n9. Not be at high-risk for suicide\n10. Not be actively psychotic\n\nInclusion Criteria (caregivers):\n\n1. Be a caregiver (biological parent, stepparent, grandparent, aunt\u002Funcle, or another adult who provides care) to an SGMY of color between the ages of 14 to 25\n2. Be over the age of 18\n3. Read and speak English\n4. Live in the United States\n5. Report consistent access to a phone, tablet, and\u002For computer with high-speed internet access.\n6. Report an ability to attend nine, two-hour online sessions at pre-determined times.\n7. Be aware of the SGM youth's minority identity\n8. NOT identify as SGM\n9. Report spending time with participating youth at least 5 waking hours per week\n10. Not be at high-risk for suicide\n11. Not be actively psychotic","14 Years",{"count":134,"type":20},180,[136],"PHASE2","Research shows that sexual and gender minority youth (SGMY) experience high rates of mental health problems and other challenges (e.g., social, academic). A major factor that leads to these challenges is family rejection (family behaviors and reactions that minimize, deny, ridicule and attempt to prevent or change a child's sexual orientation, gender identity and gender expression). Racial and ethnic minority youth experience the highest rates of family rejection and related health risks.\n\nThe Family Acceptance Project (FAP) is a research, education, and intervention initiative that was founded more than 20 years ago to help diverse families learn to support and affirm their SGMY. FAP's Family Support Model is grounded in the lived experiences of diverse SGMY and families and uses a culture-based family support framework that enables parents and caregivers to change rejecting behaviors that FAP's research has shown contribute to health risks and increase supportive and accepting behaviors that promote well-being for SGMY.\n\nThe overall goal of this research project is to evaluate a nine-week online version of FAP's Family Support Model (FAP-O). The investigators will specifically study how FAP-O:\n\n1. Promotes parent\u002Fcaregiver acceptance and support of their sexual and gender minority youth.\n2. Increases family bonding and communication.\n3. Increases SGMYs' feelings of pride in being LGBTQ+ and more hopeful about the future.\n4. Leads to reductions in mental health problems reported by SGMY who experience family rejection.\n\nBefore receiving FAP-O's family support services, racial and ethnic minority SGMY (ages 14 to 25) and their caregivers will complete an initial pre-test survey. After completing this initial (baseline) survey, half of the families will participate in program sessions. Following the first round of sessions, all participants will complete an immediate follow-up survey, with an additional survey conducted six months after this. These surveys help us learn if FAP-O impacts the project's goals above. After the final survey, the other half of the families will attend program sessions. The investigators will also ask SGMY and caregivers to share what they liked about the program and their guidance for enhancing it.",[139,140,141,142,55,143,27,144,145],"LGBTQ","Racial Disparities","Family Relationships","Minority Stress","Anxiety","Teen Dating Violence","Sexual Risk Reduction",[139,147,148,149,150,151],"Family Support","Parents of LGBTQ Youth","Racial\u002FEthnic Minority","Health Equity","Family Acceptance","2026-02-08",{"date":154,"type":32},"2026-02-11",{"date":156,"type":32},"2025-04-24",{"date":158,"type":20},"2026-12",{"name":160,"class":39},"University of Michigan",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":21,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":123},"100557662","reducing-stigma-in-people-who-inject-drugs-pwid-with-hiv-using-a-rapid-start-antiretroviral-therapy-intervention-art-100557662","NCT06541028","Reducing Stigma in People Who Inject Drugs (PWID) With HIV Using a Rapid Start Antiretroviral Therapy Intervention (ART)","Reducing Stigma in People Who Inject Drugs With HIV Using a Rapid Start Antiretroviral Therapy Intervention (RS-ART)","RS-ART","Inclusion Criteria:\n\nPWID in general population:\n\n* Be a PWID from the general population enrolling into ART services at one of the study's HIV clinics. PWID can include patients injecting opioids, amphetamines, or other combinations of injectable drugs. Some of these patients may be diagnosed with Opioid Use Disorder (OUD).\n* Provide informed consent.\n* HIV clinicians prescribing ART\n\n  1. Be the HIV clinician who prescribes ART for a PWID in one of the selected clinics.\n  2. Be willing to use the RS-ART protocol.\n  3. Be at least 18 years old. No minors below age 18 will be enrolled in the study.\n  4. Provide informed consent.\n\nPWID in prison population:\n\n* Be a PWID enrolling into ART services at Kajang prison. PWID can include patients injecting opioids, amphetamines, or other combinations of injectable drugs. Some of these patients may be diagnosed with Opioid Use Disorder (OUD).\n* Provide informed consent.\n\nExclusion Criteria:\n\n\\-",{"count":170,"type":20},135,[23],"This study seeks to develop an RS-ART implementation strategy by utilizing the Delphi method and interviewing experts and PWID regarding their experiences with ART. This strategy will then be pilot tested in a randomized controlled trial (Aim 3). The research will not impact the type of medication and dose prescribed, but rather, how soon providers are able to prescribe ART after diagnosis. The focus of this registration is Aim 3.",[174,27],"Hiv","2026-01-28",{"date":177,"type":32},"2026-01-29",{"date":179,"type":32},"2025-11-04",{"date":181,"type":20},"2028-05",{"name":91,"class":39},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":15,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":21,"phases":193,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":213},"100618063","lakota-family-acceptance-project-100618063","NCT07326748","Lakota Family Acceptance Project","Development and Evaluation of an Indigenized Family Acceptance Project for Lakota LGBTQ2S+ Youth","L-FAP","Youth Inclusion Criteria:\n\n* Identify as 2SLGBTQ+ (and their identity must be known to their participating caregiver)\n* Identify as Indigenous (multiracial youth who are also Indigenous are eligible)\n* Youth should be between the ages of 13 and 18 years\n* Read and speak English\n* Report moderate to high levels of caregiver\u002Ffamily rejection (as evidenced by agreement on items that assess the presence and frequency of specific family rejecting behaviors \\[includes ambivalent and moderately and highly rejecting caregivers\\]\n* Report an ability and commitment to attending eight sessions at two hours a week over eight weeks with their caregiver\n\nParticipating Caregiver Inclusion Criteria:\n\n* Caregivers are broadly defined and may include a biological parent, stepparent, grandparent, aunt\u002Funcle, or other adult who provides care to the Indigenous 2SLGBTQ+ youth\n* Must be over the age of 18\n* Read and speak English\n* Be aware of the SGM identity of their Indigenous 2SLGBTQ+ youth\n* report an ability and commitment to attending eight sessions at two hours a week over eight weeks with their teen\n\nExclusion Criteria:\n\n* We will exclude Indigenous 2SLGBTQ+ youth and caregivers at imminent risk for suicide and\u002For who are experiencing current psychosis symptoms as determined by results on the safety items screener.",{"count":192,"type":20},28,[23],"The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.",[139,140,141,142,55,143,27,144,145],[197,139,198,199,200,201,149,202,203,204],"family acceptance","2SLGBTQ+","youth","family support","parents of LGBTQ youth","health equity","Native American\u002FIndigenous","Two Spirit","2026-01-23",{"date":207,"type":32},"2026-01-26",{"date":209,"type":32},"2026-01-20",{"date":211,"type":20},"2027-01-31",{"name":160,"class":39},2,{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":222,"briefSummary":223,"conditions":224,"keywords":230,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":213},"100524027","syringe-service-based-telemedicine-and-social-network-driven-hiv-prevention-service-implementation-100524027","NCT06103370","Syringe Service Based Telemedicine and Social Network Driven HIV Prevention Service Implementation","Inclusion Criteria:\n\nInclusion criteria for index participants:\n\n* Aged 18 or older\n* Self-reported injection drug use in the prior month\n* Accessed services at the SSP in the prior 3 months\n* Willing to undergo training and attend weekly booster group sessions\n* Able to recruit at least 1 drug use Network Member (NM) into study\n* Willing to talk with peers about PWID topics such as HIV prevention and care\n* Not previously enrolled in the study as index or NM\n* English-speaking\n\nInclusion criteria for network member participants:\n\n* Aged 18 or older\n* Self-reported injection drug use in the prior month\n* Have a valid coupon or able to recall the 3-digit ID number\n* Not previously enrolled in the study as index or NM\n* English-speaking\n\nExclusion criteria:\n\n• Individuals lacking the capacity to consent",{"count":221,"type":20},360,[23],"The goal of this clinical trial is to evaluate the effectiveness of a social network intervention to recruit people who inject drugs and their networks for HIV testing and linkage to HIV prevention and treatment services in Maryland. Study aims are to determine the effectiveness of a social network driven intervention to increase:\n\n* HIV testing (primary);\n* PrEP knowledge;\n* Uptake of HIV services and pre-exposure prophylaxis (PrEP);\n* Uptake of medication for opioid use disorder (MOUD) initiation.\n\nEligible participants who access syringe service programs (SSPs) serving two counties in Maryland and their risk network members (NMs) will be recruited using an established network inventory and coupon recruitment method. When an index successfully recruits NMs, the index-NM cluster will be randomized to either a peer-educator intervention arm or an equal-attention control arm. Index participants randomized to the peer-educator intervention arm will complete a training program adapted with stakeholder input to context that emphasizes effective communication, frequent HIV testing, and awareness of evidence-based HIV prevention and treatment services. An important innovation to the network intervention will be training indexes to use and distribute HIV self-test kits and naloxone to their NMs. Index participants randomized to the equal-attention control arm will receive training sessions focused on the opioid overdose epidemic and will not include any training to serve as a peer educator. All participants (indexes and NMs) will complete study assessments at baseline and at 3 and 9 months. We will compare the peer-educator intervention group and the equal-attention control group on rates of HIV testing, knowledge of PrEP options and resources, and rates of initiation of HIV treatment, PrEP, and MOUD treatment since the previous assessment (past 3 or 6 months).",[225,226,227,228,27,229],"HIV Infections","Substance Use Disorders","Addiction","Opioid Use","Intravenous Drug Usage",[231,232,233],"Injection Drug Use","HIV Prevention","Social Networks","2025-11-06",{"date":236,"type":32},"2025-11-10",{"date":238,"type":32},"2025-10-28",{"date":240,"type":20},"2028-11",{"name":242,"class":39},"Johns Hopkins University",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":252,"phases":4,"briefSummary":253,"conditions":254,"keywords":256,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":276,"locationsCount":278},"100546453","low-dead-space-injecting-equipment-distribution-program-for-people-who-inject-drugs-in-low--and-middle-income-countries-100546453","NCT06395129","Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries","Implementing a Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries: a Process and Outcome Evaluation","Inclusion Criteria:\n\n* Aged ≥18 years (note that country-specific protocols may include participants aged ≥16 where appropriate and relevant);\n* Reporting a history of recent (past month) injection drug use;\n* Accessing the NSP to receive injecting equipment at either a facility, mobile service or through outreach and have an accompanying assigned program unique ID;\n* Able to understand and communicate in the local language(s);\n* If self-reporting HCV\u002FHIV negative status, interested in and agreeing to undergo HCV and HIV testing; and\n* Willing and able to provide informed consent to take part in the study.\n\nExclusion Criteria:\n\n* N\u002FA",{"count":251,"type":20},2400,"OBSERVATIONAL","Implementation and evaluation of a distribution program for low dead-space syringes\u002Fneedles (LDSS\u002FN) in Armenia, Georgia, and Tanzania, Egypt, Nigeria, Vietnam, India, Ukraine, and South Africa. This study aims to generate evidence on best practice LDSS\u002FN distribution programs which will enhance acceptability and sustain high levels of LDSS\u002FN uptake.\n\nPeople who inject drugs and access needle and syringe programs will be invited to attend up to three focus group discussion rounds (with 25 participants in each focus group round) to inform and provide feedback on a concurrent distribution program of LDSS\u002FN.\n\nThroughout distribution, a cohort study will be run alongside distribution with 240 participants enrolled per country (with the exception of Nigeria, where 480 participants will be recruited) who will undergo HIV and HCV testing and answer surveys on their sociodemographic and behavioral status. Key informant interviews will also be held with participating staff and stakeholders to evaluate the feasibility and acceptability of this program.\n\nPrimary outcomes assessed through this study include 1) community values and preferences for LDSS\u002FN, 2) barriers and facilitators to accessing LDSS\u002FN, 3) feasibility and effectiveness of the distribution program on increasing LDSS\u002FN uptake, 4) model the potential public health impact and cost effectiveness of LDSS\u002FN distribution in this setting.",[27,255,174],"Hepatitis",[257,258,259,260,261,262,263,264,265,266,108,267,268,269],"Low dead-space needles and syringes","Qualitative interviews","LDSS\u002FN","High dead space needles\u002Fsyringes (HDSS\u002FN)","Rapid diagnostic test (RDT)","Feasibility","Acceptability","Cost effectiveness","Modelling","Focus group discussions","Values and preferences","Needle and syringe exchange program","Blood borne virus","2025-09-25",{"date":272,"type":32},"2025-10-01",{"date":274,"type":32},"2024-09-13",{"date":158,"type":20},{"name":277,"class":39},"Médecins du Monde",9,{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":15,"sex":16,"minAge":286,"maxAge":287,"enrollmentInfo":288,"targetDuration":4,"studyType":21,"phases":290,"briefSummary":291,"conditions":292,"keywords":295,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":312},"100471990","mental-health-in-primary-care-100471990","NCT05426057","Mental Health in Primary Care","Scaling a Parenting Evidence Based Intervention (EBI) for Latinx Youth Mental Health in Primary Care","Inclusion Criteria:\n\n1. Female and male adolescents, who self-identify as Hispanic (or Latino(a))\n2. Adolescent between the ages of 12 - 16 years\n3. Adolescent living with an adult primary caregiver who is willing to participate\n4. Families must have broadband internet access on a device, including (but not limited to) a smartphone, iPad, tablet, computer at their home or other location (e.g., school, library, etc.)\n5. Families screening positive on poor family communication (a score of less than 75 on the communication measure; see measures) or youth reporting elevated depressive or anxiety symptom scores (defined as 70 to 90 on the K-CAT) or a history of suicide behavior (ideation or attempts).\n\nExclusion Criteria:\n\n* Families reporting plans to move out of the South Florida area during the study period.","12 Years","16 Years",{"count":289,"type":20},468,[23],"The goal of this study is to evaluate in an effectiveness-implementation type I hybrid trial, an enhanced version of eHealth Familias Unidas for reducing depressive, anxious symptoms and suicide behavior in Hispanic youth. The study will use a randomized rollout design with 18 pediatric primary care clinics in the South Florida area.",[293,294,27],"Depression, Anxiety","Suicide",[296,297,298,299,300,301,59,302,303],"effectiveness-implementation type 1 hybrid trial","Latinx mental health in primary care","Latinx adolescent","eHealth intervention","Familias Unidas","intervention sustainment","family functioning","sexual risk behavior","2025-08-04",{"date":306,"type":32},"2025-08-06",{"date":308,"type":32},"2022-04-26",{"date":310,"type":20},"2026-11-30",{"name":68,"class":39},17,{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":21,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":4},"100541584","development-of-a-multilevel-hiv-prevention-intervention-for-the-emergency-department-100541584","NCT06331767","Development of a Multilevel HIV Prevention Intervention for the Emergency Department","mSYNC: an mHealth SYNdemic-based Consultation-liaison HIV Prevention Intervention for the Emergency Department","mSYNC","Inclusion Criteria:\n\n* At least 18 years old\n* No HIV positive test in electronic medical record or self-reported\n* Past month HIV risk behavior (condomless sex or needle sharing not protected by adherent PrEP \\[pre-exposure prophylaxis\\])\n* Past month use of illicit drugs (excluding marijuana)\n* Belong to at least one of key HIV risk group (transgender woman, MSM, Black\u002FLatinx\u002FIndigenous)\n* Own a smartphone\n* Able to read and understand English\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Medical or psychiatric condition that would interfere with ability to participate in study procedures\n* Presented to the emergency department (ED) for a psychiatric issue\n* Expected to be admitted to ED for more than 48 hours",{"count":322,"type":20},100,[23],"The goal of this clinical trial is to pilot test a psychosocial-behavioral mobile health (mHealth) human immunodeficiency virus (HIV) prevention intervention in people who use drugs presenting to the emergency department (ED). The main question the study aims to answer is: is the intervention acceptable and appropriate? Participants will use the mHealth app while waiting in the ED and also at home for 90 days. Participants will be asked to complete surveys at baseline, before leaving the ED, and at 30-, 60-, and 90-day follow up visits.",[81,27,326,327,328,329],"Mental Health","Psychological Distress","Social Marginalization","Problems With Access to Health Care","2025-03-26",{"date":332,"type":32},"2025-04-01",{"date":334,"type":20},"2026-06",{"date":336,"type":20},"2029-04",{"name":338,"class":39},"Brigham and Women's Hospital",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":21,"phases":349,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":40},"100446131","phase-4-morning-versus-bedtime-dosing-of-antihypertensive-medication-100446131","NCT05089448","Morning Versus Bedtime Dosing of Antihypertensive Medication","Morning Versus Bedtime Dosing of Antihypertensive Medication in Grade 1 Day-night Hypertension: a Multicenter Randomized Controlled Trial (Dosing-Time Trial)","Inclusion Criteria:\n\n1. Male or female patients aged 18-70 years old;\n2. Never treated for hypertension or stopped using antihypertensive drugs for at least 2 weeks;\n3. In the two screenings,the clinical systolic BP should be in the range of 140-159 mmHg, the diastolic BP \\\u003C 100 mmHg;\n4. The average 24-hour systolic BP ≥130mmHg, daytime systolic BP ≥ 135 mmHg, and nighttime systolic BP ≥ 120 mmHg;\n5. The average of bilateral brachial-ankle pulse wave velocity ≥14m\u002Fs;\n6. Be willing to participate in the trial, sign the informed consent form, and be able to visit doctors by himself or herself.\n\nExclusion Criteria:\n\n1. Secondary hypertension;\n2. Concomitant obstructive sleep apnea (STOP-BANG score ≥ 5), insomnia, Parkinson's syndrome, or nocturnal polyuria and other diseases that affect nighttime BP;\n3. Need to work at night;\n4. Ambulatory BP monitoring was invalid (\\\u003C70% valid readings, or \\\u003C20 daytime readings or \\\u003C7 nighttime readings);\n5. Concomitant diseases that need taking medications influencing BP;\n6. Coronary heart disease, myocardial infarction or stroke within recent 6 months;\n7. Atrial fibrillation or frequent arrhythmia;\n8. Abnormal liver function exemplified as an increased alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBL) over the double of the upper limit of normal range; abnormal renal function exemplified as a serum creatinine ≥176 µmol\u002FL; and plasma potassium ≥5.5 mmol\u002FL or ≤3.5mmol\u002FL;\n9. Pregnant or lactating women;\n10. Contraindications of angiotensin II receptor blocker or calcium channel blocker;\n11. Other concomitant diseases which are considered not suitable to participate in the trial, such as thyroid diseases, acute infectious diseases, chronic mental diseases, tumor, etc.","70 Years",{"count":348,"type":20},300,[350],"PHASE4","Previous studies have shown that elevated nighttime blood pressure (BP) was more closely associated with cardiovascular mortality and morbidity than daytime and clinic BPs. With increasingly advanced technology, not only 24-hour ambulatory but also home BP monitors can be used to evaluate nighttime BP. The validation study of the Omron HEM 9601T showed that the wrist-type home BP monitor could be a suitable and reliable tool for the diagnosis and management of nocturnal hypertension. However, up to now, there is no data on home nighttime BP in Chinese patients and it is unclear if different dosing time would reduce ambulatory and home nighttime BPs differently.\n\nThe investigators therefore designed a multicenter randomized clinical trial to compare between morning dosing and bedtime dosing of antihypertensive medications in the difference in nighttime, daytime and the 24-h BP reductions evaluated by both ambulatory and home BP monitoring, and in target organ protections.",[353,354,27],"Hypertension","Blood Pressure","2025-01-03",{"date":357,"type":32},"2025-01-06",{"date":359,"type":32},"2021-01-28",{"date":361,"type":20},"2026-09-30",{"name":363,"class":39},"Yan Li",{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":21,"phases":373,"briefSummary":374,"conditions":375,"keywords":383,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":40},"100547247","phase-2-naliri-xeloxak104-for-first-line-treatment-of-advanced-pdac-100547247","NCT06405490","NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC","Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in Combination With Cadonilimab for First-Line Treatment of Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma : A Single-arm, Phase II Study","Inclusion Criteria:\n\n1. Age ≥18, male or female;\n2. Has histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC);\n3. Has not received prior systemic treatment for their locally advanced or metastatic PDAC;\n4. Has presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST 1.1);\n5. Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status;\n6. Has a life expectancy of at least 3 months;\n7. Has adequate organ function;\n8. If female of childbearing potential, have a negative serum pregnancy test within 7 days prior to first trial treatment;\n9. If female of childbearing potential or a male subject with a partner with childbearing potential, be willing to use a highly effective method of contraception (with a failure rate of less than 1.0% per year) from first study treatment to 24 weeks after completion of the trial treatment.\n\nExclusion Criteria:\n\n1. Untreated active CNS metastasis or leptomeningeal metastasis.\n2. Is currently participating and receiving an investigational drug or has participated in a study of an investigational drug within 4 weeks or within 5 times of half-life (no less than 2 weeks), whichever is shorter prior to the first dose of trial treatment;\n3. Has received other anti-tumor treatment within 4 weeks or within 5 times of half-life (no less than 2 weeks), whichever is shorter prior to the first trial treatment;\n4. Major surgery for any reason, except diagnostic biopsy, within 4 weeks of the first administration of trial treatment and\u002For if the subject has not fully recovered from the surgery within 4 weeks of the first administration of trial treatment;\n5. Curative radiation within 3 months of the first dose of trial treatment. Radiation to more than 30% of the bone marrow or with a wide field of radiation should not be used within 4 weeks prior to the first administration of trial treatment;\n6. Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment (with the exception of subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement doses, equivalent to \\\u003C 10 mg prednisone daily, inhaled steroids and topical use of steroids);\n7. Vaccination within 28 days of the first administration of trial treatment, except for administration of inactivated vaccines (e.g., inactivated influenza vaccines);\n8. Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management;\n9. History or current active autoimmune disease that might deteriorate when receiving an immunostimulatory agent；\n10. Previous malignant disease History of uncontrolled intercurrent illness Prior therapy with any antibody\u002Fdrug targeting T cell coregulatory proteins Known severe hypersensitivity reactions to antibody drug；\n11. Is pregnant or breastfeeding;\n12. Other medical conditions that at the discretion of investigator interfere with the requirements of the trial in terms of safety or efficacy evaluation, or treatment compliance.",{"count":372,"type":20},30,[136],"This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.",[376,377,378,379,380,381,382,27],"Nanoliposomal Irinotecan","Cadonilimab","Oxaliplatin","Capecitabine","First-Line","Advanced Cancer","Pancreatic Adenocarcinoma",[382,376,377,384,385],"First-Line Treatment","Advanced Pancreatic Adenocarcinoma","2024-12-19",{"date":388,"type":32},"2024-12-24",{"date":390,"type":32},"2024-04-17",{"date":392,"type":20},"2026-12-30",{"name":394,"class":39},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":15,"sex":16,"minAge":402,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":21,"phases":405,"briefSummary":406,"conditions":407,"keywords":408,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":419,"locationsCount":40},"100337298","clinical-pharmacist-intervention-to-reduce-drug-related-readmissions-among-older-people-100337298","NCT03671629","Clinical Pharmacist Intervention to Reduce Drug-related Readmissions Among Older People","Involving Clinical Pharmacists in Transitional Care to Reduce Drug-related Readmissions Among the Elderly - a Randomized Controlled Trial","Inclusion Criteria:\n\n* Living at home\n* Acutely admitted\n* Registered at one of ten pre-specified primary care health centers\n\nExclusion Criteria:\n\n* Patients unable to communicate or who do not speak Swedish\n* Patients scheduled for palliative care\n* Patients admitted due to intoxication by alcohol or drug (non prescription)","75 Years",{"count":404,"type":20},700,[23],"This randomized controlled trial primarily investigates if a clinical pharmacist intervention can reduce drug-related readmissions among patients \\>75 years. The intervention targets the transfer between hospital and primary care. In brief, the intervention includes medical chart reviews and patient interviews during a period of 180 days.",[27],[409,410,411,412],"Clinical pharmacist","Elderly","Adherence","Drug-related readmission","2024-12-17",{"date":415,"type":32},"2024-12-20",{"date":417,"type":32},"2018-09-19",{"date":158,"type":20},{"name":420,"class":39},"Umeå University",{"id":422,"slug":423,"hasResults":11,"nctId":424,"briefTitle":425,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":252,"phases":4,"briefSummary":430,"conditions":431,"keywords":437,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":123},"100554367","active-pharmacovigilance-study-of-the-medicine-rinvoq-upadacitinib-100554367","NCT06498167","Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)","LOOK-UP","Inclusion Criteria:\n\n* Prescription of Rinvoq™ from January 1, 2024;\n* 18 years of age or older at the time of recruitment; and\n* Expressed consent to participate in the study.\n\nExclusion Criteria:\n\n* They have any degree of cognitive impairment that prevents them from responding to a questionnaire administered by telephone;\n* They are participating in a phase I, II, or III clinical trial;\n* They have a life expectancy of less than 1 month; or\n* They do not have a valid telephone contact.",{"count":429,"type":20},150,"The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. The Marketing Authorisation Holder is AbbVie Deutschland GmbH \\& Co. KG.",[432,433,27,434,435,436],"Inflammatory Disease","Drug Side Effect","Adverse Drug Event","Adverse Drug Reaction","Safety Issues",[438,439,440,441,442,443,444,445,446,447,448],"Upadacitinib","Rinvoq","Rheumatoid arthritis","Psoriatic arthritis","Axial spondyloarthritis","Atopic dermatitis","Ulcerative colitis","Crohn's disease","Pharmacovigilance risk","Drug safety monitoring","Patient Safety","2024-07-12",{"date":451,"type":32},"2024-07-15",{"date":453,"type":32},"2024-07-01",{"date":455,"type":20},"2024-12-31",{"name":457,"class":39},"Universidade do Porto",{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":15,"sex":16,"minAge":464,"maxAge":132,"enrollmentInfo":465,"targetDuration":4,"studyType":21,"phases":467,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":40},"100468513","developing-a-positive-approach-to-substance-use-prevention-in-north-american-indian-adolescents-100468513","NCT05380765","Developing a Positive Approach to Substance Use Prevention in North American Indian Adolescents","Inclusion Criteria - Youth Participants:\n\n1. residing in the First Nation community,\n2. identify as a member of a First Nation,\n3. be in grades 5th - 8th at time of enrollment, and\n4. one youth per household may participate.\n\nInclusion Criteria - Family Participants:\n\n1. at least 18 years of age\n2. reside within the First Nation community\n3. be identified, by the youth, as an important influence in their life\n4. be committed to helping the youth make good decisions regarding using substances","10 Years",{"count":466,"type":20},60,[23],"The overall objective of this project is to develop and obtain preliminary data on acceptability, feasibility, and initial efficacy of Native PATHS. This work is guided by the stage model guidelines for treatment development and adaptation 25. Stage 1a will occur in two sequential steps. First, the investigators will recruit youth who are in 5th - 8th grade and their family members (N=24, 12 youth, 12 adults 18+) to participate in three talking circle sessions to obtain feedback on the cultural adaptation and implementation of the treatment. Next, the investigators will conduct an open label pilot (N=9). Youth and their family members, (up to 3 per youth) will provide qualitative and quantitative feedback after each session. In Stage 1b, 60 youth will participate in a pilot randomized controlled trial, testing the efficacy of the newly created program (n=30) against a wait list control (WLC) condition (n=30). Ultimately, this program of research is expected to result in a well-specified, efficacious prevention program that could be readily disseminated and generalizable to other Indigenous populations with minimal adaptation.",[470,471,27],"Alcohol Drinking","Tobacco Use","2024-06-04",{"date":474,"type":32},"2024-06-05",{"date":476,"type":20},"2024-06-17",{"date":478,"type":20},"2025-05-31",{"name":480,"class":39},"University of Rhode Island"]